S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
NASDAQ:GMAB

Genmab A/S (GMAB) Stock Price, News & Analysis

$29.29
+1.52 (+5.47%)
(As of 03/1/2024 ET)
Today's Range
$28.58
$29.48
50-Day Range
$26.43
$32.77
52-Week Range
$26.32
$42.99
Volume
551,844 shs
Average Volume
698,175 shs
Market Capitalization
$19.35 billion
P/E Ratio
30.51
Dividend Yield
N/A
Price Target
$48.50

Genmab A/S MarketRank™ Stock Analysis

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
65.5% Upside
$48.50 Price Target
Short Interest
Healthy
0.35% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.46mentions of Genmab A/S in the last 14 days
Based on 23 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
37.61%
From $1.09 to $1.50 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.07 out of 5 stars

Medical Sector

200th out of 957 stocks

Pharmaceutical Preparations Industry

84th out of 440 stocks


GMAB stock logo

About Genmab A/S Stock (NASDAQ:GMAB)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

GMAB Stock Price History

GMAB Stock News Headlines

Truist Financial Reaffirms Their Buy Rating on Genmab (GMAB)
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Genmab's SBLA For Epcoritamab-bysp Granted Priority Review By FDA
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
Transactions in connection with share buy-back program
Genmab (GMAB) Gets a Buy from Truist Financial
GMAB Mar 2024 35.000 put
Genmab A/S's (GMAB) "Buy" Rating Reaffirmed at HC Wainwright
Genmab A/S's (GMAB) "Buy" Rating Reaffirmed at Truist Financial
Transactions in connection with share buy-back program
GMAB Mar 2024 30.000 call
GMAB Mar 2024 25.000 put
See More Headlines
Receive GMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/01/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GMAB
Fax
N/A
Employees
2,204
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$48.50
High Stock Price Target
$50.00
Low Stock Price Target
$46.00
Potential Upside/Downside
+65.6%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
13 Analysts

Profitability

Net Income
$631.91 million
Pretax Margin
34.22%

Debt

Sales & Book Value

Annual Sales
$2.39 billion
Cash Flow
$1.31 per share
Book Value
$6.95 per share

Miscellaneous

Free Float
650,570,000
Market Cap
$19.35 billion
Optionable
Optionable
Beta
0.99

Social Links

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. Jan G.J. van de Winkel Ph.D. (Age 63)
    Co-Founder, President & CEO
    Comp: $2.74M
  • Mr. Anthony Pagano (Age 46)
    Executive VP & CFO
    Comp: $1.02M
  • Mr. Anthony Mancini (Age 53)
    Executive VP & COO
    Comp: $1.11M
  • Mr. Martin Schultz (Age 48)
    Senior Director of Clinical Operations & Non-Independent Director
    Comp: $72.93k
  • Dr. Judith V. Klimovsky M.D. (Age 66)
    Executive VP & Chief Development Officer
    Comp: $1.15M
  • Dr. Tahamtan Ahmadi (Age 51)
    Executive VP, Chief Medical Officer & Head of Experimental Medicines
    Comp: $1.09M
  • Dr. Mijke Zachariasse Ph.D. (Age 50)
    Senior Director, Head of Antibody Research Materials & Non-Independent Director
    Comp: $145.87k
  • Mr. Takahiro Hamatani (Age 49)
    Senior Director of Finance Japan & Non-Independent Director
    Comp: $72.93k
  • Mr. Andrew Carlsen
    Senior Director, VP & Head of Investor Relations
  • Ms. Birgitte Stephensen M.Sc. (Age 63)
    Executive VP & Chief Legal Officer

Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Genmab A/S was last updated on Tuesday, February 27, 2024 at 4:05 PM.

Pros

Here are some ways that investors could benefit from investing in Genmab A/S:

  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases, showing a commitment to addressing critical medical needs.
  • The company has a diverse product portfolio including DARZALEX, teprotumumab, ofatumurnab, and Amivantamab, targeting various types of cancer and diseases, providing revenue streams from multiple sources.
  • Genmab A/S has active pre-clinical programs and collaborations with reputable companies like Seagen Inc., CureVac AG, and AbbVie, indicating a strong pipeline for future growth and innovation.
  • The company's stock price has shown consistent growth in recent periods, reflecting positive investor sentiment and potential for further appreciation.
  • Genmab A/S has a solid track record of successful antibody therapeutics development, enhancing investor confidence in the company's research and development capabilities.

Cons

Investors should be bearish about investing in Genmab A/S for these reasons:

  • Genmab A/S operates in the pharmaceutical industry, which is subject to regulatory challenges, market competition, and risks associated with clinical trials, impacting the company's financial performance and stock volatility.
  • The success of Genmab A/S heavily relies on the approval and commercial success of its products in development, posing a risk of setbacks or failures in the drug development process.
  • Investing in biopharmaceutical companies like Genmab A/S involves inherent risks related to intellectual property protection, market acceptance of new therapies, and potential disruptions in supply chains, affecting the company's revenue and profitability.
  • The pharmaceutical sector is sensitive to macroeconomic factors, healthcare policies, and global health crises, leading to uncertainties in demand for medical treatments and impacting Genmab A/S's financial performance.
  • Genmab A/S's stock price may be influenced by market volatility, industry trends, and investor sentiment, resulting in fluctuations that could affect the value of investments in the company.














GMAB Stock Analysis - Frequently Asked Questions

Should I buy or sell Genmab A/S stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last year. There are currently 3 sell ratings, 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares.
View GMAB analyst ratings
or view top-rated stocks.

What is Genmab A/S's stock price target for 2024?

13 brokerages have issued 12-month price targets for Genmab A/S's stock. Their GMAB share price targets range from $46.00 to $50.00. On average, they anticipate the company's stock price to reach $48.50 in the next year. This suggests a possible upside of 65.5% from the stock's current price.
View analysts price targets for GMAB
or view top-rated stocks among Wall Street analysts.

How have GMAB shares performed in 2024?

Genmab A/S's stock was trading at $31.84 at the start of the year. Since then, GMAB stock has decreased by 8.0% and is now trading at $29.30.
View the best growth stocks for 2024 here
.

When is Genmab A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our GMAB earnings forecast
.

How were Genmab A/S's earnings last quarter?

Genmab A/S (NASDAQ:GMAB) announced its quarterly earnings data on Wednesday, November, 10th. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.10. The company had revenue of $366.25 million for the quarter, compared to analyst estimates of $341.46 million. Genmab A/S had a net margin of 26.50% and a trailing twelve-month return on equity of 18.06%. During the same quarter in the prior year, the firm earned $0.13 earnings per share.

What guidance has Genmab A/S issued on next quarter's earnings?

Genmab A/S updated its FY 2024 earnings guidance on Wednesday, February, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.7 billion-$3.0 billion, compared to the consensus revenue estimate of $2.8 billion.

What other stocks do shareholders of Genmab A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), Home Depot (HD), Intel (INTC), Pfizer (PFE), PayPal (PYPL), Verizon Communications (VZ) and Cisco Systems (CSCO).

When did Genmab A/S IPO?

(GMAB) raised $503 million in an initial public offering on Thursday, July 18th 2019. The company issued 27,800,000 shares at a price of $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.

Who are Genmab A/S's major shareholders?

Genmab A/S's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Capital International Investors (0.61%), Harding Loevner LP (0.50%), First Trust Advisors LP (0.19%), Envestnet Asset Management Inc. (0.14%), Stifel Financial Corp (0.10%) and Royal Bank of Canada (0.10%).

How do I buy shares of Genmab A/S?

Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GMAB) was last updated on 3/1/2024 by MarketBeat.com Staff